ERS Research Seminar

Pharmacology of asthma and COPD: current and future developments

10 – 11 June 2021; Napoli, Italy

Day 1 – Thursday, 10 June 2020

08:45-09:00   Registration
09:00-09:10   Welcome and introduction

Session 1: Pharmacology of asthma and COPD - current knowledge
09:10-09:30   Understanding the mechanism of action of bronchodilators in asthma and COPD
09:30-09:40   Discussion
09:40-10:00   How do inhaled steroids work and interact in asthma and COPD?
10:00-10:10   Discussion
10:10-10:30   Biomarker guided pharmacological intervention
10:30-10:40   Discussion
10:40-11:10   General discussion

11:10-11:30   Coffee break

Session 2: Challenges for clinical development
11:30-12:00   Key challenges faced during clinical development of anti-inflammatory drugs for asthma and COPD
12:00-12:30   General discussion

12:30-13:30   Lunch

Session 3: Emerging new concepts and treatments
13:30-13:50   Do we understand remodeling in asthma and COPD?
13:50-14:00   Discussion
14:00-14:20   Lung regeneration: is it still far from reality?
14:20-14:30   Discussion
14:30-14:50   Emerging classes of drugs for the treatment of obstructive lung disease
14:50-15:00   Discussion

15:00-17:30   Session 4 – Breakout: what is this seminar’s position on the selection of treatment in asthma and COPD?
15:00-15:15   Explain tasks and operating methods
15:30-16:15   Session 1 - Identifying surrogate markers and outcomes
  •   Which surrogate markers can be used to assess and quantify disease in a pre-clinical stage? Do we need drug intervention in pre-clinical detectable disease?
• Which are the read-outs to assess drug effect in the progression of the disease?
• Is an effect on remodeling required for drug efficacy? If so, how to assess it?

16:15-17:00  **Session 2 - How do we select treatments for patients with severe asthma and COPD?**

- What is non-clinical evidence to sustain combination therapy including ICS in COPD? What about LABA/LAMA in asthma?
- Are there realistic treatment goals for monoclonal antibodies in COPD? How do they differ from asthma?
- Which features suggest considering patients for non-pharmacological, i.e. bronchoscopic interventions in asthma and COPD?

17:00-17:30  **Round table**

**Day 2 – Friday, 11 June 2020**

09:00-09:30  Summary of day 1 and possible output, next steps and plenary discussion

**Session 5: Challenges in the treatment of patient with asthma and COPD**

09:30-09:50  New insights into steroid resistance
09:50-10:00  Discussion
10:00-10:20  Comorbidities and drug interactions
10:20-10:30  Discussion
10:30-10:50  Pharmacogenetics of asthma and COPD and treatment
10:50-11:00  Discussion
11:00-11:20  General discussion

11:20-11:40  **Coffee break**

11:40-12:20  **Session 6 – Breakout: what is this seminar’s position on the selection of treatment in asthma and COPD?**

11:40-11:50  Explain tasks and operating methods

11:50-12:20  **Session 1 - How to streamline clinical and basic research**

- How to translate relevant clinical questions to experiments?
- How to translate experimental data to clinical practice?
- Which themes should be prioritized?
- How can academia and industry cooperate?

12:20-12:50  **Round table**

12:50-13:00  Conclusion

13:00-14:00  **Lunch and Departure**